Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
HIV/AIDS
Research from J.G. Joyce and colleagues provide new insights into HIV/AIDS
December 31st, 2008
According to recent research published in the journal Proceedings of the National Academy of Sciences of the United States of America, "The conserved oligomannose epitope, Man(9)GlcNAC(2), recognized by the broadly neutralizing human mAb 2G12 is an attractive prophylactic vaccine candidate for the prevention of HIV-1 infection. We recently reported total chemical synthesis of a series of glycopeptides incorporating one to three copies of Man(9)GlcNAc(2) coupled to a cyclic peptide scaffold." "Surface plasmon resonance studies showed that divalent and trivalent, but not monovalent, compounds were capable of binding 2G12. To test the efficacy of the divalent...
Source: Vaccine Weekly (2008-12-31)
|
